Abstract Sacubitril/valsartan (LCZ696), a supramolecular sodium salt complex of the
neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment
of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

Abstract Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular
sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …

We performed a meta-analysis investigating the efficacy and adverse effects of sacubitril–
valsartan in various types of heart failure including more recent studies and a larger sample …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …